The identification of a ROS1-GOPC fusion has significant clinical implications due to the established anti-cancer activity of tyrosine kinase inhibitors (TKIs) in tumors that carry ROS1 rearrangements.[19–21] The ROS1 tyrosine kinase inhibitor (TKI) crizotinib shows marked clinical efficacy in TKI-naive ROS1-positive patients in clinical trials, with an overall response of 65% to 72% and an expected median progression-free survival of 19 months. This evidence concerns the gene ROS1 and cancer.